Risankizumab
Skyrizi from AbbVie wins a maintenance trial for ulcerative colitis and is poised to receive FDA approval
SG Tylor
Source – Abbvie On 16 June 2023, Risankizumab (SKYRIZI, 180 mg or 360 mg subcutaneous [SC]) achieved the primary endpoint ...
